SCHEMBL608266

SCHEMBL608266

O=C(O)c1cc(NCCc2ccccc2Cl)ccc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX4 Q9NPH5 3/20 0.61
EGFR P00533 2/20 0.51
ALDH1A1 P00352 2/20 0.51
MAPT P10636 2/20 0.51
RGS12 O14924 1/20 0.51
LCK P06239 1/20 0.51
CAMKK2 Q96RR4 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
MCL1 Q07820 3/20 0.51
PPARA Q07869 1/20 0.50
STING1 Q86WV6 1/20 0.50
KDM4C Q9H3R0 2/20 0.49
CNR1 P21554 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HIF1A Q16665 1/20 0.45
MEN1 O00255 1/20 0.45
RECQL P46063 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29391103 1.00 NOX4 (0.61) NOX4EGFRALDH1A1MAPTRGS12
SCHEMBL4089718 0.86 CA1 (0.53) NOX4EGFRALDH1A1MAPTRGS12
SCHEMBL607633 0.84 NOX4 (0.61) NOX4EGFRALDH1A1MAPTRGS12
SCHEMBL4093950 0.82 NOX4 (0.59) NOX4EGFRALDH1A1MAPTRGS12
SCHEMBL608754 0.82 NOX4 (0.61) NOX4EGFRALDH1A1MAPTRGS12
SCHEMBL607105 0.81 NOX4 (0.57) NOX4EGFRALDH1A1MAPTRGS12
SCHEMBL29389796 0.81 NOX4 (0.57) NOX4EGFRALDH1A1MAPTRGS12
SCHEMBL29391568 0.79 KDM4C (0.53) NOX4EGFRALDH1A1MAPTRGS12
SCHEMBL610065 0.79 KDM4C (0.53) NOX4EGFRALDH1A1MAPTRGS12
SCHEMBL610123 0.78 SYK (0.58) NOX4EGFRALDH1A1MAPTRGS12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3902536-B1 COMPOSITIONS COMPRISING 5-BENZYLAMINOSALICYLIC ACID COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS IN A COMPANION ANIMAL GNT PHARMA CO LTD (KR) 2025-09-03 EP claimed
EP-4456890-A2 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS GNT Pharma Co., Ltd (KR) 2024-11-06 EP claimed
WO-2023156808-A2 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS GNT PHARMA CO., LTD. (KR) 2023-08-24 WO claimed
US-20230233503-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS GNT PHARMA CO., LTD. (KR) 2023-07-27 US claimed
US-20220249343-A1 COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF GNT PHARMA CO., LTD. (KR) 2022-08-11 US claimed
US-20220241231-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT PHARMA CO., LTD. (KR) 2022-08-04 US claimed
CN-114096227-A Cosmetic compositions comprising 5-benzylaminosalicylic acid derivatives and methods of topical use thereof 吉恩特药业株式会社 2022-02-25 CN claimed
CN-113710242-A Compositions and methods for treating neurodegenerative disorders 吉恩特药业株式会社 2021-11-26 CN claimed
EP-3902536-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT Pharma Co., Ltd (KR) 2021-11-03 EP claimed
US-20200206172-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT PHARMA CO., LTD. (KR) 2020-07-02 US claimed
WO-2020136441-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT PHARMA CO., LTD. (KR) 2020-07-02 WO claimed
US-20130316988-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2013-11-28 US claimed
US-8455470-B2 Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases NEUROTECH PHARMACEUTICALS CO., LTD (KR) 2013-06-04 US claimed
US-20120040939-A1 MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2012-02-16 US claimed
CN-102316863-A The medical usage of 5-benzylamino salicyclic acid derivatives or its salt NEUROTECH PHARMACEUTICALS CO L 2012-01-11 CN claimed
US-20090281181-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases GNT PHARMA CO., LTD. (KR) 2009-11-12 US claimed
US-20090149542-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2009-06-11 US claimed
EP-2004164-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES Neurotech Co., Ltd. (KR) 2008-12-24 EP claimed
US-20070298129-A1 Compounds and compositions for treating neuronal death or neurological dysfunction NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2007-12-27 US claimed
WO-2007119973-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES NEUROTECH CO., LTD. (KR) 2007-10-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149542-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION BCL2, BAX, SMN1; SMN2 NOX4 2363/4885EGFR 2671/4885ALDH1A1 1961/4885
US-20230233503-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS HAO2, ACOX1, HAO1 NOX4 195/4885EGFR 3946/4885ALDH1A1 309/4885
US-20220241231-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS PRNP, PSEN1, GRIK5 NOX4 4612/4885EGFR 3139/4885ALDH1A1 859/4885
US-20070298129-A1 Compounds and compositions for treating neuronal death or neurological dysfunction BCL2, BAX, SMN1; SMN2 NOX4 2363/4885EGFR 2671/4885ALDH1A1 1961/4885
US-20120040939-A1 MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT HTR5A, HTR6, MC5R NOX4 1222/4885EGFR 3070/4885ALDH1A1 133/4885
US-20090281181-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B NOX4 1202/4885EGFR 2155/4885ALDH1A1 446/4885
US-20130316988-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B NOX4 1202/4885EGFR 2155/4885ALDH1A1 446/4885
US-20220249343-A1 COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF ALOX5, ALOX15, IL5 NOX4 1921/4885EGFR 4006/4885ALDH1A1 93/4885
US-20200206172-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS PRNP, PSEN1, GRIK5 NOX4 4612/4885EGFR 3139/4885ALDH1A1 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.